Cefazolin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Cefazolin: From Bacterial Infections to Infectious Otitis Media
One-Sentence Summary
Cefazolin is a first-generation cephalosporin antibiotic. Its SAHPRA record does not state an approved indication, so the original use here is taken from the drug class. The TxGNN model predicts it may be effective for infectious otitis media, but there are no registered clinical trials and only 3 indirect publications (two reviews and one case report) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA record (approved indication text is empty) |
| Predicted New Indication | Infectious otitis media |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Cefazolin is a beta-lactam antibiotic, and beta-lactams inhibit bacterial cell wall synthesis. That activity could plausibly cover Gram-positive bacteria that cause ear infections, such as Streptococcus and Staphylococcus species.
There are important limits. Cefazolin’s coverage of Haemophilus influenzae and Moraxella catarrhalis, two common causes of otitis media, is weak. It is also given by injection only, which is a poor fit for a condition usually treated with oral antibiotics.
The score is very high, but no trials or direct human evidence support it. The prediction should be read as a hypothesis from the knowledge graph, not as a validated new use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3742953 | 1986 | Review | Clinical Pharmacy | Stevens-Johnson syndrome case and review. The child was treated for otitis media with penicillin and cefaclor, not cefazolin. Indirect. |
| 877649 | 1977 | Review | Southern Medical Journal | General review of cephalosporins in paediatric infections. Not specific to cefazolin or otitis media. |
| 39567876 | 2025 | Case report | Annals of Otology, Rhinology, and Laryngology | Ceftazidime-cefazolin empiric therapy for paediatric Gradenigo syndrome, a rare complication of acute otitis media. Anecdotal only. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 36/20.1.1/0259 | Sabax cefazolin powder for injection | Injection | Not stated in the record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there are no clinical trials and the literature is indirect. Cefazolin’s spectrum has known gaps against key otitis media pathogens, and the injection-only route limits practical use.
To proceed, the following is needed:
- The SAHPRA Professional Information (PI), to confirm the approved indications, warnings and contraindications, and to allow a safety screen.
- Mechanism of action data from DrugBank.
- Direct clinical evidence in otitis media. A modern comparative study, or a check of current local pathogen susceptibility, would help.
- Review of related predictions. Chronic otitis media and suppurative otitis media have one direct human comparative study (PMID 6752467, 1982, cefmetazole vs cefazolin, 172 evaluable patients) and are rated L3. They are stronger research questions than this one, though that study is dated and antibiotic resistance patterns have changed since.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.